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probability of prescribing brand name antidiabetics. CONCLUSIONS: DM diagnosis 
implies a relevant economic impact, has a high cost to society. The price regulation 
in 2006 to 2009 was able to generate the proﬁt and decresing the share of pharma 
expenditure in total health expenditure while increasing access new to drugs, and 
keeping the copayments low.
PDB69
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(T2DM) EXPERIENCE MORE DELAYED TREATMENT WITH  
ORAL ANTIHYPERGLYCEMIC AGENTS COMPARED WITH  
YOUNGER PATIENTS
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OBJECTIVES: This study compared older (≥ 65 yrs) and younger patients with newly 
diagnosed T2DM, and evaluated factors associated with oral antihyperglycemic agent 
(OAHA) initiation. METHODS: This retrospective cohort study used U.S. General 
Electric (GE) Centricity electronic medical record database. Patients aged ≥30 yrs with 
newly-diagnosed T2DM (January-2003 to December-2005) were included. There was 
no diabetes diagnosis or treatment within 2 years prior to the ﬁrst recorded T2DM 
diagnosis. Medical records 1 year prior to (baseline) and 2 years after (follow-up) 
diagnosis were extracted. OAHA initiation was estimated based on the ﬁrst OAHA 
prescription during follow-up. Multivariable Cox proportional hazards regression 
model was ﬁtted. Untreated patients were censored at complete 2 years follow-up. 
RESULTS: Among 10,760 newly diagnosed T2DM patients, 55% were female. Mean 
age at T2DM diagnosis was 61.3( ± 12.5), with 4,617 (43%) ≥65 yrs. At baseline, 
older relative to younger patients had lower HbA1c (6.7% vs. 7.2%, with only 38% 
vs. 32% attaining HbA1c < 7% goal), lower fasting blood glucose (117.9 vs. 132.8 mg/
dL) and lower BMI (30.6 vs. 35.2), higher rates of acute myocardial infarction (MI) 
(2.1% vs. 0.9%), heart failure (5.1% vs. 1.8%), stroke (3.1% vs. 0.8%), and renal 
disease (17.5% vs. 6.2%), and more co-medications (all p-values < 0.05). Within 2 
years after T2DM diagnosis, 56% older and 40.5% younger patients (P < 0.001) had 
not received OAHA. Older patients were less likely to be treated than younger patients 
(adjusted hazard ratio 0.84, p < 0.001). Additionally, patients with baseline MI 
or renal disease were less likely to be treated (p < 0.05). Higher BMI or HbA1c at 
baseline, and heart failure, initiating antihypertensive or lipid lowering drugs after 
T2DM diagnosis were factors associated with increased likelihood of OAHA treat-
ment (p < 0.05). CONCLUSIONS: Older patients with newly diagnosed T2DM had 
milder hyperglycemia but more comorbidities, and experienced more delayed OAHA 
therapy than younger patients.
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OBJECTIVES: To evaluate the dosing of sitagliptin for type 2 diabetes mellitus 
(T2DM) patients with renal impairment. METHODS: This was a retrospective cross-
sectional analysis using the General Electric Electronic Medical Records. The study 
population (N = 1539) was patients with T2DM and renal impairment (deﬁned 
using ICD-9-CM codes) who were prescribed sitagliptin between April 1, 2006 and 
June 30, 2008. Based on the label, 100mg of sitagliptin is the recommended dose 
for patients with normal or mild renal impairment (CrCl≥50), 50mg for patients 
with moderate renal impairment (50 > CrCl≥30), and 25mg for severe or end-stage 
renal disease (ESRD)(30 > CrCl). Baseline severity of renal impairment was deter-
mined using calculated GFR values using the 4-point Modiﬁcation of Dosing in 
Renal Disease (MDRD) formula. Patients with GFR level ≥60 were considered normal 
to mild cases, 30 to < 60 were moderate cases, 15 to <30 were severe cases, and 
<15 or patients on dialysis had ESRD. Univariate analysis was done on age, gender, 
race, US region, payment source, comorbidities and Charlson-comorbidity index 
to identify factors that may be associated with inappropriate dosing. RESULTS: 
Of the 1,539 renally impaired patients with T2DM who received sitagliptin, 
804(52%) had moderate renal impairment and 158(11%) had severe renal impair-
ment or ESRD. Two-thirds of all moderate to severe and ESRD renally impaired 
patients had initial sitagliptin prescriptions that were higher-than-recommended 
doses. At 12-month follow-up, 87% of patients, whose initial prescription was for 
a higher-than-recommended-dose of sitagliptin, continued to be on the inappropriate 
higher dose. Univariate analysis showed there were no signiﬁcant differences 
in dosing by age, gender, race, US region, insurance type or comorbidities. 
CONCLUSIONS: Indiscriminant of patient characteristics, 2/3’s of the population 
of sitagliptin users recommended a lower dose due to renal impairment, were found 
to be inappropriately dosed higher-than-recommended. This inappropriate dosing 
was not corrected during a year-long follow-up.
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OBJECTIVES: Understanding affects of care organization and continuity of care on 
potentially preventable hospitalizations for diabetes complications (DC) is important 
for policy development and outcomes management. We determined DC rates among 
Medicaid beneﬁciaries and assessed associations between care organization and DC. 
METHODS: A retrospective cohort analysis of Indiana Medicaid claims, enrollment, 
and encounter data was conducted. Sample inclusion criteria were ≥18 y/o, diabetes 
based on ICD-9 codes or NDC codes for diabetes speciﬁc medications, and continuous 
eligibility in 2008. Exclusion criteria were a nursing home stay or no claims in 2008. 
DCs were identiﬁed based on AHRQ diabetes prevention quality indicators for short-
term complications, uncontrolled diabetes, long-term complications and amputations. 
Each individual was placed in one of four groups based on whether continuously 
enrolled in Fee for Service (FFS), Care Management (CM), Managed care (MC), or 
whether switches between subprograms occurred in 2008. Persons enrolled in CM 
entered through disability determination, while other groups had no known disability 
indication. Logistic regression assessed association between Medicaid subprogram and 
DC adjusting for age, gender, ethnicity, marital status, diabetes type, mental illness, 
hypertension, coronary artery disease, foot speciﬁc conditions and Charlson comor-
bidity index. RESULTS: A sample of 47,443 persons, with mean age of 53 years, 68% 
female and, 77% white was identiﬁed. Overall, 1,514 hospitalizations for DC (95% 
C.I., 1439 - 1592) with a rate of 31.9 per 1000 individuals with diabetes was found. 
Although no signiﬁcant difference was seen between CM or MC as compared to FFS, 
DCs were more likely in individuals who switched subprograms than those in FFS 
(Odds ratio = 1.6, 95% C.I.: = 1.4 – 1.9, p≤0.001). CONCLUSIONS: Transitions 
between Medicaid subprograms was associated with greater likelihood of diabetes 
complication hospitalization. CM may reduce adverse outcomes for those persons 
with medical disability. Continuity of care may be essential.
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BACKGROUND AND OBJECTIVES: Diabetes is a chronic, potentially disabling 
and often fatal disease. The International Diabetes Federation estimates that more 
than 245 million people around the world are living with diabetes. Around 3.2 
million deaths are attributable to complication of diabetes every year; six deaths 
every minute. Pakistan is in the top ten countries in the number of sufferers from 
diabetes. This disease requires continuing proper medical care and patient self-
management education to prevent complications Current study aims to observe the 
current standard in the management of diabetic at a private tertiary care hospital 
in Karachi, Pakistan. METHODS: A retrospective health record review was done 
at a private tertiary care hospital at Karachi, Pakistan. Health records for all the 
persons with diabetes, who visited general physician or family physician during the 
months of April and May 2007, were included in this study. Two indicators includ-
ing foot examination and advice for HbA1C diagnostic test for this cross sectional 
survey were identiﬁed. Data were analyzed using descriptive statistics. RESULTS: 
Total 350 health records were reviewed and of these, 40% were males and 60 
females. Majority of the diabetics (80%) were over the age of 50 years. We found 
that only 40% of the patients were physically checked for foot examination and 
advised for HbA1C lab investigation by their general physician or family physician. 
About 44% were not either checked for foot examination or advised for HbA1C. 
CONCLUSIONS: Diabetes is a devastating chronic disease and can result in death 
very early if not managed properly. Current study suggest that adherence to the 
current screening guidelines was inadequate in this practice setting. Adherence to 
current diabetes management guidelines and diabetes care quality improvement initia-
tives can result in signiﬁcant improvements in the provision and documentation of 
diabetes care.
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OBJECTIVES: Determined how treatment of type 2 diabetes with drug therapy 
mirrors the accepted published clinical guidelines (for example those provided by the 
American Association of Clinical Endocrinologists). This included both initial drug 
therapy as well as therapies added over time. METHODS: Catalina Health Resource 
receives data from a nationally representative sample of pharmacy chains, representing 
approximately 40% of all national retail prescription volume, and comprised of over 
130 million unique patients. Data are captured daily from the pharmacies, are fully 
HIPAA compliant, longitudinal, and not projected. Patient cohort included all patients 
who initiated type 2 diabetes treatment January-March 2006. Look-back period was 
180 days and look-forward period was through December 2008. RESULTS: Patient 
cohort consisted of 77,302 new type 2 diabetes patients. Metformin is the recom-
mended initial therapy, but only 61% of patients were prescribed it as their initial 
therapy. The remaining patients began on a sulfonylurea (23%) or a thiazolidinedione 
(15%). 62% of patients who started on metformin did not add other drugs during 
the study, as compared to 48% of patients who started therapy on an SFU and 43% 
of patients who started therapy on a TZD. 1% of patients who started on metformin 
added/switched to basal insulin as their second drug, mean time to add/switch was 
547 days. 3% of patients who started on an SFU added/switched to basal insulin as 
their second drug, mean time to switch was 541 days. CONCLUSIONS: Nearly 40% 
of type 2 diabetes patients did not initiate therapy in line with published guidelines. 
Patients who initiated therapy on metformin had the highest rate of remaining on 
monotherapy. Patients who initiated therapy with metformin also had a lower rate of 
switching to/adding basal insulin as their second drug than patients who initiated 
therapy on an SFU.
